REGENXBIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.19 USD | +0.81% |
|
+3.19% | -9.81% |
Presenter SpeechEliana Merle (Analysts)I'm Ellie Merle. Very happy to have REGENXBIO here with...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
16.19
USD
Average target price
39.83
USD
Spread / Average Target
+146.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.81% | 794M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RGNX Stock
- News REGENXBIO Inc.
- Transcript : REGENXBIO Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 03
